Christophe Weber | President & CEO Andy Plump | President, R&D Costa Saroukos | Chief Financial Officer PLAY LIST from the beginning FY2021 Q3 EARNINGS ANNOUNCEMENT IMPORTANT NOTICE 1. Introduction CONVICTION IN OUR STRATEGY: ACCELERATING TOPLINE & PIPELINE TAKEDA EXECUTIVE TEAM PROGRESS WITH VACCINE PARTNERSHIPS TO COMBAT COVID-19 LAUNCHED IN Q3 WITH POTENTIAL TO REDEFINE SUCCESS IN POST-TRANSPLANT CMVINFECTION/DISEASE 2. R&D Engine UPDATES TO OUR PIPELINE SINCE Q2 ANNOUNCEMENT VONVENDI: FIRST RECOMBINANT TREATMENT FOR PROPHYLAXIS OF ADULTS WITH TYPE 3 VON WILLEBRAND DISEASE (VWD) OUR PIPELINE IS STARTING TO DELIVER VALUE PHASE 3/PIVOTAL PROGRAMS WITH UPCOMING NME APPROVAL AND EXPANSION OPPORTUNITIES PROOF-OF-CONCEPT READOUTS OVER THE NEXT TWO YEARS COULD UNLOCK SIGNIFICANT ADDITIONAL VALUE 3. Financial Strength ACCELERATION OF TOPLINE GROWTH: Q3 YTD UNDERLYING REVENUE +7.1%1DRIVEN BY 14 GLOBAL BRANDS STRONG TOPLINE GROWTH IN Q3 YTD, WITH CORE OPERATING PROFIT REFLECTING IMPACT OF DIVESTITURES UNDERLYING REVENUE MOMENTUM DRIVEN BY 14 GLOBAL BRANDS;REPORTED REVENUE BENEFITTING FROM SALE OF DIABETES PORTFOLIO UNDERLYING REVENUE GROWTH +7.1% SUPPORTED BY 5 KEY BUSINESS AREASWITH STRONG GROWTH OF GI, PDT, ONCOLOGY & NEUROSCIENCE 14 GLOBAL BRANDS REPRESENT 42% OF FY2021 Q3 YTD CORE REVENUE1WITH UNDERLYING GROWTH +12.0% GROWTH MOMENTUM OF 14 GLOBAL BRANDS EXPECTED TO CONTINUE CORE OPERATING PROFIT REFLECTS DIVESTITURE IMPACT ROBUST FY2021 Q3 YTD CASH FLOW LEADS TO INCREASE IN FULL-YEAR FREE CASH FLOW GUIDANCE TO JPY 700-800B NET DEBT/ADJUSTED EBITDA IMPROVES TO 3.0x EVEN AFTER FULL-YEAR DIVIDEND PAYMENT ABUNDANT CASHFLOW ALLOWS CALLING OF $1.5B FY2023 BOND;TOTAL PROPORTION OF FIXED RATE DEBT NOW AT 98% RAISING FULL-YEAR FY2021 FORECASTS TO REFLECT BUSINESS MOMENTUM, OPEX DISCIPLINE, AND FX FAVORABILITY ACCELERATION OF TOPLINE GROWTH: Q3 YTD UNDERLYING REVENUE GROWTH +7.1% DRIVEN BY 14 GLOBAL BRANDS Q&A SESSION Q&A 1 Q&A 2 Q&A 3 Q&A 4 Q&A 5 Q&A 6 Q&A 7 APPENDIX TAKEDA'S DISCLOSURE METRICS DEFINITION OF CORE AND UNDERLYING GROWTH DEFINITION OF FREE CASH FLOW DEFINITION OF EBITDA/ADJUSTED EBITDA AND NET DEBT GROWTH OF GI FRANCHISE SPEARHEADED BY ENTYVIO NO LONGER EXPECTING BIOSIMILAR LAUNCH UPON ANTICIPATED DATA EXCLUSIVITY EXPIRY TIMING RARE DISEASES REVENUE IN LINE WITH PLAN; NOW TREATING 3,000 PATIENTS GLOBALLY WITH TAKHZYRO PDT PORTFOLIO ON TRACK TO DELIVER FULL-YEAR GROWTH GUIDANCE STRONG ONCOLOGY PORTFOLIO CONTINUES TO EXPAND INDICATIONS VYVANSE CONTINUES REBOUND FROM PRIOR YEAR COVID-19 IMPACT FY2021 Q3 YTD (Apr-Dec) REPORTED RESULTS FY2021 Q3 (Oct-Dec) REPORTED RESULTS FY2021 Q3 YTD (Apr-Dec) CORE RESULTS FY2021 Q3 (Oct-Dec) CORE RESULTS RECONCILIATION FROM REPORTED REVENUE TO CORE/UNDERLYING REVENUE FY2021 Q3 YTD VERSUS PRIOR YEAR RECONCILIATION FROM REPORTED REVENUE TO CORE/UNDERLYING REVENUE FY2021 Q3 (Oct-Dec)VERSUS PRIOR YEAR RECONCILIATION FROM REPORTED TO CORE/UNDERLYINGFY2021 Q3 YTD RECONCILIATION FROM REPORTED TO CORE/UNDERLYINGFY2021 Q3 (Oct-Dec) RECONCILIATION FROM REPORTED TO CORE/UNDERLYINGFY2020 Q3 YTD RECONCILIATION FROM REPORTED TO CORE/UNDERLYINGFY2020 Q3 (Oct-Dec) FREE CASH FLOW NET DEBT/ADJUSTED EBITDA NET PROFIT TO ADJUSTED EBITDA BRIDGE FY2021 Q3 YTD VERSUS PRIOR YEAR NET PROFIT TO ADJUSTED EBITDA LTM BRIDGE FY2021 DETAILED REVISED FORECAST FY2021 CORE OPERATING PROFIT ADJUSTMENT ITEMS & CASH FLOW FORECAST VERSUS ACTUALS RECONCILIATION FROM REPORTED OPERATING PROFIT TO CORE OPERATING PROFIT-FY2021 REVISED FORECAST FX RATES AND FY2021 CURRENCY SENSITIVITY OUR PIPELINE CONTINUES TO ADVANCE CONTINUED GLOBAL AND REGIONAL BRAND EXPANSION IN FY2021 MAXIMIZING THE VALUE OF OUR GLOBAL AND REGIONAL BRANDS R&D ENGINE DRIVING WAVE 1 APPROVALS AND EXPANSION OF GLOBAL AND REGIONAL BRANDS GLOSSARY OF ABBREVIATIONS @ Back Next